Health Canada has issued a public advisory about glatiramer acetate, used to treat relapsing-remitting multiple sclerosis (MS). The agency warned on Aug. 21 that patients taking glatiramer acetate could experience anaphylactic reactions, which “can be fatal and may occur at any point during treatment, from as soon as the first dose to months or even…